Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors

被引：0
|
作者：
Toshihiko Doi
Kenji Tamura
Yuko Tanabe
Kan Yonemori
Takayuki Yoshino
Nozomu Fuse
Makoto Kodaira
Hideaki Bando
Kazuo Noguchi
Takashi Shimamoto
Atsushi Ohtsu
机构：
[1] National Cancer Center Hospital East,Exploratory Oncology Research & Clinical Trial Center
[2] National Cancer Center Hospital,undefined
[3] National Cancer Center,undefined
[4] MSD K.K.,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2015年 / 76卷
关键词：
MK-2206; pan-AKT inhibitor; Pharmacokinetics; Phase I study; Skin toxicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：409 / 416
页数：7
相关论文
共 50 条
  • [21] A phase I dose escalation study of oral MK-2206 (allosteric Akt inhibitor) with oral selumetinib (AZD6244; ARRY-142866) (MEK 1/2 inhibitor) in patients with advanced or metastatic solid tumors.
    Khan, Khurum Hayat
    Yan, Li
    Mezynski, Janusz
    Patnaik, Amita
    Moreno, Victor
    Papadopoulos, Kyriakos P.
    Garrett, Chris R.
    Ong, Michael
    Shannon, Keith A.
    Morosky, Anne
    Rubin, Eric H.
    Tetteh, Ernestina
    Skolnik, Jeffrey
    Smith, Ian C.
    Smith, Paul D.
    De Bono, Johann Sebastian
    Tolcher, Anthony W.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers
    Yap, Timothy A.
    Yan, Li
    Patnaik, Amita
    Tunariu, Nina
    Biondo, Andrea
    Fearen, Ivy
    Papadopoulos, Kyriakos P.
    Olmos, David
    Baird, Richard
    Delgado, Liliana
    Tetteh, Ernestina
    Beckman, Robert A.
    Lupinacci, Lisa
    Riisnaes, Ruth
    Decordova, Shaun
    Heaton, Simon P.
    Swales, Karen
    deSouza, Nandita M.
    Leach, Martin O.
    Garrett, Michelle D.
    Sullivan, Daniel M.
    de Bono, Johann S.
    Tolcher, Anthony W.
    CLINICAL CANCER RESEARCH, 2014, 20 (22) : 5672 - 5685
  • [23] Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors.
    Biondo, A.
    Yap, T. A.
    Yan, L.
    Patnaik, A.
    Fearen, I.
    Baird, R. D.
    Papadopoulos, K. P.
    Delgado, L. M.
    Taylor, A.
    Lupinacci, L.
    Blackman, S. C.
    Decordova, S.
    Tall, M.
    Heaton, S.
    Garrett, M. D.
    Sullivan, D.
    De Bono, J. S.
    Tolcher, A. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [24] Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer
    Wisinski, Kari B.
    Tevaarwerk, Amye J.
    Burkard, Mark E.
    Rampurwala, Murtuza
    Eickhoff, Jens
    Bell, Maria C.
    Kolesar, Jill M.
    Flynn, Christopher
    Liu, Glenn
    CLINICAL CANCER RESEARCH, 2016, 22 (11) : 2659 - 2667
  • [25] Phase II study of the oral AKT inhibitor, MK-2206, for acute myeloid leukemia (AML) in second relapse.
    Konopleva, Marina Y.
    Walter, Roland B.
    Faderl, Stefan
    Jabbour, Elias
    Zeng, Zhihong
    Borthakur, Gautam
    Ruvolo, Peter
    Huang, Xuelin
    Kadia, Tapan
    Feliu, Jennie
    Burger, Jan A.
    Andreeff, Michael
    Liu, Wenbin
    Kornblau, Steven M.
    Baggerly, Keith
    Estey, Elihu
    Kantarjian, Hagop
    CANCER RESEARCH, 2013, 73 (08)
  • [26] Discovery of MK-2206: The first oral allosteric Akt kinase inhibitor for the treatment of cancer
    Kelly, Michael J., III
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 244
  • [27] Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia
    Richter, Anna
    Fischer, Elisabeth
    Holz, Clemens
    Schulze, Julia
    Lange, Sandra
    Sekora, Anett
    Knuebel, Gudrun
    Henze, Larissa
    Roolf, Catrin
    Escobar, Hugo Murua
    Junghanss, Christian
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (05) : 1 - 17
  • [28] A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis
    Arceci, Robert J.
    Allen, Carl E.
    Dunkel, Ira J.
    Jacobsen, Eric
    Whitlock, James
    Vassallo, Robert
    Morris, Shannon R.
    Portnoy, Alison
    Reedy, Beth Ann
    Smith, Deborah A.
    Noble, Robert
    Murnane, Amy
    Cornfeld, Mark
    Rodriguez-Galindo, Carlos
    Heaney, Mark L.
    McClain, Kenneth
    Vaiselbuh, Sarah
    PEDIATRIC BLOOD & CANCER, 2017, 64 (05)
  • [29] Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors
    Minami, Hironobu
    Kawada, Kenji
    Ebi, Hiromichi
    Kitagawa, Koichi
    Kim, Yon-il
    Araki, Kazuhiro
    Mukai, Hirofumi
    Tahara, Makoto
    Nakajima, Hikaru
    Nakajima, Keiko
    CANCER SCIENCE, 2008, 99 (07): : 1492 - 1498
  • [30] A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies
    Amy Jo Chien
    Alyson Cockerill
    Craig Fancourt
    Emmett Schmidt
    Mark M. Moasser
    Hope S. Rugo
    Michelle E. Melisko
    Andrew H. Ko
    R. Katie Kelley
    W. Michael Korn
    Laura J. Esserman
    Laura van‘t Veer
    Christina Yau
    Denise M. Wolf
    Pamela N. Munster
    Breast Cancer Research and Treatment, 2016, 155 : 521 - 530
12345